GLOW 70mg
GLOW 70 mg is provisionally mapped to a three-component BPC-157, TB-500-designated, and GHK-Cu laboratory blend. For research use only (RUO); not for human or veterinary use.
Out of stock
GLOW 70mg Product Description
The GLOW nickname alone does not define composition. This preview provisionally maps it to BPC-157, a TB-500-designated material, and the copper complex GHK-Cu, while keeping the exact Lobo split and each component's molecular form unresolved. The displayed 70 mg is a nominal total for one vial.
Its page cannot establish the TB-500 sequence, GHK copper stoichiometry, component identities, compatibility, stability, purity, or measured content of this separate catalog lot.
Ingredient-level papers may guide designs with each component alone, the fully documented blend, and appropriate controls. None of the cited primary sources tested this fixed three-component formulation, so no synergy, compatibility, stability, combined performance, or combined safety is asserted. Source papers are summarized only at the level supported by their reported models, and the catalog language avoids translating experimental observations into promises.
The entry is structured for qualified laboratory review. Before publication or experimental comparison, product-specific records should resolve identity, physical form, component definition where applicable, and the relationship between the nominal label amount and any measured result. Until then, uncertainty is retained as part of the product record rather than replaced with assumptions. Each experiment should record the actual lot, reference standard, assay matrix, controls, instrument method, and acceptance criteria needed for reproducible interpretation.
Research Material Profile
GLOW 70mg Research
BPC-157 ingredient evidence
A BPC-157 study used rat Achilles-tendon explants and cultured tendon fibroblasts, measuring outgrowth, migration, oxidative-stress survival, F-actin organization, and FAK/paxillin-associated signals. Those observations concern one characterized ingredient in specified laboratory systems. The study did not include TB-500-designated material, GHK-Cu, or the provisional 10/10/50 mg formulation. It therefore cannot establish a property of GLOW as a blend. For a valid combination experiment, each ingredient would need exact identity documentation, single-component arms, the confirmed fixed formulation, and prespecified controls. The current catalog nickname and nominal total are insufficient to assign causation or interaction. This paper is included solely to document BPC-157's ingredient-level research context and does not verify the Lobo component amount or lot composition. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 21030672).
Thymosin beta-4 adjacent ingredient evidence
Defined thymosin beta-4 has been examined in cultured human endothelial-cell migration, scratch-wounded monolayers, and Matrigel-associated assays. That work concerns a specifically identified peptide and cannot establish what molecular form the TB-500-designated component in GLOW represents. Full-length thymosin beta-4, fragments, acetylated fragments, and other related materials are not interchangeable by name. The cited experiment also did not combine its test article with BPC-157 or GHK-Cu. Accordingly, it supplies adjacent ingredient context only and offers no support for blend synergy, compatibility, stability, or combined behavior. Lobo documentation must identify the TB-500 component before a researcher can select a suitable literature comparator or control. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 9194528).
GHK-Cu ingredient evidence
Primary cell-culture studies examined GHK-Cu in fibroblast systems, including normal and irradiated cultures, with biochemical or cell-associated endpoints selected by the investigators. These publications show that a defined copper-peptide complex has been used as a laboratory test article. They did not study BPC-157, TB-500, the GLOW nickname, or a 70 mg three-component vial. Copper stoichiometry, peptide identity, matrix, concentration, and cell conditions are all necessary for interpreting GHK-Cu results and cannot be inferred for this product. In a future blend study, GHK-Cu would require independent characterization and a dedicated single-ingredient control. The papers support ingredient-only context and nothing more; they do not confirm Lobo's provisional 50 mg component amount or any interaction among the three named materials. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 3169264 · PubMed 15655171).
Evidence Boundaries
The cited literature supports only the exact molecule or ingredient, model, and endpoint described in each source. It does not verify this Lobo lot, establish equivalence to another seller's material, or convert a nominal catalog amount into measured content. Cell, biochemical, microbial, ex vivo, animal, and controlled human research are not interchangeable evidence categories. Where a blend is involved, single-ingredient papers do not establish the fixed formulation, component ratio, interaction, compatibility, stability, combined performance, or combined safety. Where a fragment, probe, analogue, or related strength is involved, that distinction remains explicit. No unreported identity, sequence, termini, counterion, purity, sterility, endotoxin status, residual-solvent result, or other analytical attribute is inferred. The listing supplies research context only and includes no clinical guidance, procedural directions, or expected outcome.
GLOW 70mg References
9 curated medical and scientific references used for identity, mechanism, model, and assay context.
- Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts.
Pollard JD, Quan S, Kang T, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Archives of facial plastic surgery. 2005;7(1):27-31. doi:10.1001/archfaci.7.1.27.
GHK-Cu ingredient evidence only; proposed GLOW split unconfirmed · Normal and irradiated primary human dermal fibroblasts in serum-free culture
View research source - The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010.
BPC-157 ingredient evidence only; proposed GLOW split unconfirmed · Rat Achilles-tendon explants and cultured tendon fibroblasts
View research source - Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.
Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-x.
GHK-Cu ingredient evidence only; proposed GLOW split unconfirmed · Fibroblast cultures
View research source - Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells.
Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1997;11(6):474-81. doi:10.1096/fasebj.11.6.9194528.
Thymosin beta-4 ingredient evidence only; proposed GLOW split unconfirmed · Human endothelial-cell migration assays and Matrigel migration model
View research source - Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y.
BPC-157 ingredient evidence only; proposed GLOW split unconfirmed · Endothelial assays, chick chorioallantoic membrane, and rat hind-limb ischemia model
View research source - The actin binding site on thymosin beta4 promotes angiogenesis.
Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003;17(14):2103-5. doi:10.1096/fj.03-0121fje.
Thymosin beta-4/fragment ingredient context only; proposed GLOW split unconfirmed · Full-length thymosin beta-4, fragments, HUVEC migration, and chick aortic-arch sprouting assays
View research source - The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures.
Siméon A, Emonard H, Hornebeck W, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life sciences. 2000;67(18):2257-65. doi:10.1016/s0024-3205(00)00803-1.
GHK-Cu ingredient evidence only; proposed GLOW split unconfirmed · Cultured dermal fibroblasts
View research source - GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.
Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017;25(2):270-278. doi:10.1111/wrr.12520.
GHK-Cu formulation-specific ingredient evidence only; proposed GLOW split unconfirmed · HUVEC assays and mouse scald-wound model using GHK-Cu liposomes
View research source - Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts.
Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts. Acta poloniae pharmaceutica. 2014;71(6):954-8.
GHK/GHK-Cu ingredient evidence only; proposed GLOW split unconfirmed · Normal human dermal fibroblasts in vitro
View research source